The skin is an attractive site for drug delivery, providing the largest interface between the human body and the external environment. Skin acts as an effective barrier to drug absorption. Understanding the parameters that affect the permeability of this barrier is essential for achieving successful drug therapy via the skin. Skin permeation/penetration model is a widely used tool for the study of percutaneous absorption and the pharmacokinetic profile of topical drugs. This in vitro method is an essential tool for the development and screening of formulations, predicting in vivo cutaneous absorption. Current methods require a lot of manual intervention and are expensive and time-consuming.
In order to streamline the testing process, Almirall, through this Open innovation initiative, AlmirallShare, is seeking collaboration partners who are capable of designing an automated, high throughput system to evaluate the permeation/penetration profile, with small dosing areas and optimum receptor fluid flow to be able to generate more accurate flux profiles.
This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.
Delivery of medications through the skin has shown significant advantages in clinical practice for drug targeting to the action site in the body, reducing the systemic side effects. It is also more advantageous than traditional routes of administration (e.g. oral, intravenous) for a number of reasons such as improved patient compliance, ease of application, and avoidance of first pass metabolism.
Percutaneous absorption most commonly occurs via passive diffusion through the intercellular lipid matrix (intercellular and transcellular route) and is governed by chemical properties. For example, low molecular weight and high lipid solubility significantly enhances skin penetration. To complicate matters, the skin is a heterogeneous organ and differences occur based upon age, gender, health, and anatomical site.
In vitro skin delivery is necessary to predict the human in vivo bioavailability, efficacy and safety for topical and transdermal formulations. Successful proposals should focus on technologies and approaches capable of generating accurate permeability profiles in human and animal skin using an automated and high throughput system.
This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (maximum of 10 pages, including supporting non-confidential information and contact details) to be evaluated by Almirall with a goal of establishing a collaborative partnership. Upon completion of the evaluation, Almirall may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed time frame.
[NOTE: Only proposals from Solvers who have the ability to work as a collaboration partner will be considered.]
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on October 29, 2017.
Late submissions will not be considered.
ABOUT THE SEEKER
Almirall is a global science partner, headquartered in Barcelona, Spain, that leads the fight against skin problems and diseases - skin prevention, skin care and skin improvement – through medical solutions that provide health professionals and their patients a healthy future. Since 1943, we have supported our partners and patients in the continuous health improvement, bringing our innovative solutions where they are needed. Almirall is committed to supporting those who need us, understanding their challenges and applying science to solve them. For more information, visit http://www.almirall.com/.
AlmirallShare, Almirall Open Innovation platform, has the willingness to share efforts of those who struggle with passion to find solutions to skin diseases. It is an initiative where talent, wherever it is, works together to solve skin challenges. For more information, visit sharedinnovation.almirall.com/
What is an eRFP Challenge?
eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.
After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.
This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.